Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Comparison of Intravitreal Dexamethasone Implant and Posterior Subtenon Triamcinolone Injection in the Treatment of Diabetic Macular Edema in Vitrectomized Eyes

Comparison of Intravitreal Dexamethasone Implant and Posterior Subtenon Triamcinolone Injection... Introduction: The aim of this study was to compare posterior subtenon triamcinolone (PSTA) application and intravitreal dexamethasone phosphate (DEX) implant in the treatment of diabetic macular edema (DME) in vitrectomized eyes. Methods: This retrospective study included 64 (48.12%) patients who received PSTA and 69 (51.88%) patients who received DEX implants in DME treatment after vitrectomy. Best corrected visual acuity (BCVA), central macular thickness (CMT), and intraocular pressure (IOP) were analyzed before injection; at 1, 3, and 6 months after injection. The postinjection values were statistically compared with the preinjection value. Results: All postinjection CMT values in both groups were lower than the preinjection value (p < 0.05 for all). There were statistically significant increases in all postinjection BCVAs of the DEX group and postinjection 1-month BCVA of the PSTA group (p < 0.05 for all). However, there was no significant difference in BCVA values of the PSTA group at 3 and 6 months after injection (p > 0.05 for both). There was no statistically significant difference in all postinjection IOP values of the PSTA group (p > 0.05 for all). However, significant increases in IOP were observed in the DEX group at 1 and 3 months after injection (p < 0.05 and p = 0.02, respectively). The number of additional injections between the 3rd and 6th months after the initial injection was statistically higher in the PSTA group (p = 0.006). Conclusion: Both intravitreal DEX and PSTA administration are effective in the treatment of DME after vitrectomy. However, visual improvement persisted longer, and the need for additional injections was less in patients who received DEX. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Ophthalmologica Karger

Comparison of Intravitreal Dexamethasone Implant and Posterior Subtenon Triamcinolone Injection in the Treatment of Diabetic Macular Edema in Vitrectomized Eyes

Download PDF
7 pages

Loading next page...
 
/lp/karger/comparison-of-intravitreal-dexamethasone-implant-and-posterior-WLogzPKlBM
Publisher
Karger
Copyright
© 2022 S. Karger AG, Basel
ISSN
0030-3755
eISSN
1423-0267
DOI
10.1159/000526172
Publisher site
See Article on Publisher Site

Abstract

Introduction: The aim of this study was to compare posterior subtenon triamcinolone (PSTA) application and intravitreal dexamethasone phosphate (DEX) implant in the treatment of diabetic macular edema (DME) in vitrectomized eyes. Methods: This retrospective study included 64 (48.12%) patients who received PSTA and 69 (51.88%) patients who received DEX implants in DME treatment after vitrectomy. Best corrected visual acuity (BCVA), central macular thickness (CMT), and intraocular pressure (IOP) were analyzed before injection; at 1, 3, and 6 months after injection. The postinjection values were statistically compared with the preinjection value. Results: All postinjection CMT values in both groups were lower than the preinjection value (p < 0.05 for all). There were statistically significant increases in all postinjection BCVAs of the DEX group and postinjection 1-month BCVA of the PSTA group (p < 0.05 for all). However, there was no significant difference in BCVA values of the PSTA group at 3 and 6 months after injection (p > 0.05 for both). There was no statistically significant difference in all postinjection IOP values of the PSTA group (p > 0.05 for all). However, significant increases in IOP were observed in the DEX group at 1 and 3 months after injection (p < 0.05 and p = 0.02, respectively). The number of additional injections between the 3rd and 6th months after the initial injection was statistically higher in the PSTA group (p = 0.006). Conclusion: Both intravitreal DEX and PSTA administration are effective in the treatment of DME after vitrectomy. However, visual improvement persisted longer, and the need for additional injections was less in patients who received DEX.

Journal

Ophthalmologica – Karger

Published: Nov 1, 2022

Keywords: Posterior subtenon triamcinolone; Dexamethasone implant; Diabetic macular edema; Pars plana vitrectomy

References

  • Effectiveness of intravitreal dexamethasone implant treatment for diabetic macular edema in vitrectomized eyes
    Özdemir, HB; Hasanreisoğlu, M; Yüksel, M; Ertop, M; Gürelik, G; Özdek, Ş
  • Surgical management of diabetic retinopathy
    Gupta, V; Arevalo, JF
  • Diabetic vitrectomy in a large type 1 diabetes patient population: long-term incidence and risk factors
    Ostri, C; la Cour, M; Lund-Andersen, H
  • Inflammation and macular oedema after pars plana vitrectomy
    Romano, V; Angi, M; Scotti, F; del Grosso, R; Romano, D; Semeraro, F
  • Efficacy of intravitreal triamcinolone acetonide for diabetic macular edema after vitrectomy
    Watanabe, A; Tsuzuki, A; Arai, K; Gekka, T; Kohzaki, K; Tsuneoka, H
  • Intravitreal pharmacokinetics after posterior subtenon triamcinolone acetonide injection in vitrectomized rabbit eyes
    Park, HJ; Lee, JE; Kim, SI; Pak, KY; Oum, BS; Lee, JS
  • Comparison of vitrectomized with nonvitrectomized eyes after subtenon injection of triamcinolone acetonide to treat diabetic macular edema: retrospective comparative analysis of an interventional case series
    Pak, KY; Choi, BS; Park, SW; Byon, IS; Lee, JE
  • Effect of dexamethasone intravitreal implant in vitrectomized and nonvitrectomized eyes of Taiwanese patients with treatment-naïve diabetic macular edema
    Wang, JK; Huang, TL; Chang, PY
  • Efficacy and safety of postvitrectomy intravitreal triamcinolone therapy for diabetic macular edema
    Costa, JF; Sousa, K; Marques, JP; Marques, M; Cachulo, ML; Silva, R
  • Bevacizumab (Avastin) for diabetic macular edema in previously vitrectomized eyes
    Yanyali, A; Aytug, B; Horozoglu, F; Nohutcu, AF
  • Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients
    Boyer, DS; Faber, D; Gupta, S; Patel, SS; Tabandeh, H; Li, XY
  • Pharmacokinetics of a sustained-release dexamethasone intravitreal implant in vitrectomized and nonvitrectomized eyes
    Chang-Lin, JE; Burke, JA; Peng, Q; Lin, T; Orilla, WC; Ghosn, CR
  • Sustained-release steroids for the treatment of diabetic macular edema
    Daruich, A; Matet, A; Behar-Cohen, F
  • Effectiveness and safety of intravitreal dexamethasone implant (Ozurdex) in patients with diabetic macular edema: a real-world experience
    Mello Filho, P; Andrade, G; Maia, A; Maia, M; Biccas Neto, L; Muralha Neto, A
  • Intravitreal dexamethasone implant in patients with persistent diabetic macular edema
    Zucchiatti, I; Lattanzio, R; Querques, G; Querques, L; Del Turco, C; Cascavilla, ML
  • Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema
    Campochiaro, PA; Brown, DM; Pearson, A; Ciulla, T; Boyer, D; Holz, FG
  • Dexamethasone intravitreal implant in vitrectomized versus nonvitrectomized eyes for treatment of patients with persistent diabetic macular edema
    Medeiros, MD; Alkabes, M; Navarro, R; Garcia-Arumí, J; Mateo, C; Corcóstegui, B
  • Evaluation of efficacy and safety of dexamethasone intravitreal implants of vitrectomized and nonvitrectomized eyes in a real world study
    Rezkallah, A; Malclès, A; Dot, C; Voirin, N; Agard, É; Vié, AL
  • Vitreous concentrations of triamcinolone acetonide in human eyes after intravitreal or subtenon injection
    Inoue, M; Takeda, K; Morita, K; Yamada, M; Tanigawara, Y; Oguchi, Y
  • Short-term efficacy of intravitreal dexamethasone implant in vitrectomized eyes with recalcitrant diabetic macular edema and prior anti-VEGF therapy
    Shah, AR; Xi, M; Abbey, AM; Yonekawa, Y; Faia, LJ; Hassan, TS
  • Trans-Tenon’s retrobulbar injection of triamcinolone acetonide for diffuse diabetic macular edema
    Wada, M; Ogata, N; Minamino, K; Koriyama, M; Higuchi, A; Matsumura, M
  • Posterior sub-tenon’s steroid injections for the treatment of posterior ocular inflammation: indications, efficacy and side effects
    Lafranco Dafflon, M; Tran, VT; Guex-Crosier, Y; Herbort, CP
  • Role of inflammation in classification of diabetic macular edema by optical coherence tomography
    Chung, YR; Kim, YH; Ha, SJ; Byeon, HE; Cho, CH; Kim, JH
  • Optical coherence tomography for complete management of patients with diabetic retinopathy
    Oshitari, T; Mitamura, Y
  • Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema
    Aiello, LP; Bressler, NM; Edwards, AR; Friedman, SM; Miller, KM
  • Predicting outcomes to anti-vascular endothelial growth factor (VEGF) therapy in diabetic macular oedema: a review of the literature
    Ashraf, M; Souka, A; Adelman, R
  • Ranibizumab plus prompt or deferred laser for diabetic macular edema in eyes with vitrectomy before antivascular endothelial growth factor therapy
    Bressler, SB; Melia, M; Glassman, AR; Almukhtar, T; Jampol, LM; Shami, M
  • Imaging and biomarkers in diabetic macular edema and diabetic retinopathy
    Kwan, CC; Fawzi, AA
  • The correlation between fluorescein angiographic and optical coherence tomographic features in clinically significant diabetic macular edema
    Kang, SW; Park, CY; Ham, D-I
  • Long-term efficacy and duration of action of dexamethasone implant, in vitrectomised and non-vitrectomised eyes with persistent diabetic macular oedema
    Bastakis, GG; Dimopoulos, D; Stavrakakis, A; Pappas, G
  • Real-world retrospective comparison of 0.19 mg fluocinolone acetonide and 0.7 mg dexamethasone intravitreal implants for the treatment of diabetic macular edema in vitrectomized eyes
    Coelho, J; Malheiro, L; Melo Beirão, J; Meireles, A; Pessoa, B
  • Efficacy of sub-tenon’s capsule injection of triamcinolone acetonide for refractory diabetic macular edema after vitrectomy
    Sato, H; Naito, T; Matsushita, S; Takebayashi, M; Shiota, H
  • Complications of intravitreal injection of triamcinolone acetonide
    Özkiriş, A; Erkilic¸, K